Proton beam therapy is an advanced form of external radiotherapy that uses high-energy proton beams instead of photon x-ray beams or electrons. Carefully measured doses of protons are delivered to the precise area needing treatment, using the latest IBA ProteusONE technology. This ensures that the delivery of proton beam therapy is highly accurate and prevents the risk of radiation reaching surrounding healthy tissue.
Radiotherapy is used to kill and destroy cancer cells. It utilises radiation in the form of high-energy x-rays, known as photons, to kill and damage the cancerous cells and prevent their growth and reproduction. It can be used as a non-surgical option to treat cancer, and it can also be used to shrink a tumour or in combination with other treatments.
The Rutherford Cancer Centres and Elekta are bringing the next generation of personalised adaptive radiotherapy technology to oncology centres across the UK, with the new MR-linac Elekta Unity now available at the Rutherford Cancer Centre North West in Liverpool.
Gastrointestinal cancer refers to malignant conditions of the gastrointestinal (GI) tract and accessory organs of digestion, including the oesophagus, stomach, biliary system, liver, pancreas, small intestine, large intestine, rectum and anus. Overall, the GI tract and the accessory organs of digestion are responsible for more cancers and more deaths from cancer than any other system in the body.
Worldwide, hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third leading cause of cancer-related deaths. HCC is relatively uncommon in the United States, although its incidence is rising, principally in relation to the spread of hepatitis C virus (HCV) infection. The incidence of pancreatic carcinoma has markedly increased over the past several decades and ranks as the fourth leading cause of cancer death in the United States. The incidence of oesophagal cancer has risen in recent decades and is the eighth most common cancer globally.
This white paper aims to provide existing clinical data when considering treatment options that benefit patients the most.
IBA White Paper
*Please refer to the Terms and Conditions of this website when leaving the site and viewing third party content.
This page was printed directly from www.therutherford.com/crpublications/treating-gastrointestinal-malignancy-with-proton-therapy on 23 Sep 2021, 05:43pm and is correct at the time of printing. Please note: this website is updated periodically and information may be amended or deleted if required. Please refer back to the website to ensure the information is correct at the time of enquiry.